Cargando…
Targeted Therapies for Melanoma
The incidence of cutaneous malignant melanoma is increasing worldwide. Despite available modern therapeutical options, long-term survival of patients in advanced stages of the disease remains rather limited until now. Detailed insights into etiopathogenesis and mechanisms of tumour progression enabl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565572/ https://www.ncbi.nlm.nih.gov/pubmed/32899184 http://dx.doi.org/10.3390/cancers12092494 |
_version_ | 1783595963599814656 |
---|---|
author | Smetana, Karel Lacina, Lukáš Kodet, Ondřej |
author_facet | Smetana, Karel Lacina, Lukáš Kodet, Ondřej |
author_sort | Smetana, Karel |
collection | PubMed |
description | The incidence of cutaneous malignant melanoma is increasing worldwide. Despite available modern therapeutical options, long-term survival of patients in advanced stages of the disease remains rather limited until now. Detailed insights into etiopathogenesis and mechanisms of tumour progression enable physicians to manipulate distinct molecular structures and pathways therapeutically and so treat the tumour. Unfortunately, the acquisition of therapeutic resistance frequently terminates these therapeutical interventions. The presented special issue is focusing on the research and therapeutic experience of leading scientists, and it summarises the state of the art of targeted therapy of melanoma and suggests the new perspectives of the treatment of disease. |
format | Online Article Text |
id | pubmed-7565572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75655722020-10-26 Targeted Therapies for Melanoma Smetana, Karel Lacina, Lukáš Kodet, Ondřej Cancers (Basel) Editorial The incidence of cutaneous malignant melanoma is increasing worldwide. Despite available modern therapeutical options, long-term survival of patients in advanced stages of the disease remains rather limited until now. Detailed insights into etiopathogenesis and mechanisms of tumour progression enable physicians to manipulate distinct molecular structures and pathways therapeutically and so treat the tumour. Unfortunately, the acquisition of therapeutic resistance frequently terminates these therapeutical interventions. The presented special issue is focusing on the research and therapeutic experience of leading scientists, and it summarises the state of the art of targeted therapy of melanoma and suggests the new perspectives of the treatment of disease. MDPI 2020-09-03 /pmc/articles/PMC7565572/ /pubmed/32899184 http://dx.doi.org/10.3390/cancers12092494 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Editorial Smetana, Karel Lacina, Lukáš Kodet, Ondřej Targeted Therapies for Melanoma |
title | Targeted Therapies for Melanoma |
title_full | Targeted Therapies for Melanoma |
title_fullStr | Targeted Therapies for Melanoma |
title_full_unstemmed | Targeted Therapies for Melanoma |
title_short | Targeted Therapies for Melanoma |
title_sort | targeted therapies for melanoma |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565572/ https://www.ncbi.nlm.nih.gov/pubmed/32899184 http://dx.doi.org/10.3390/cancers12092494 |
work_keys_str_mv | AT smetanakarel targetedtherapiesformelanoma AT lacinalukas targetedtherapiesformelanoma AT kodetondrej targetedtherapiesformelanoma |